Vispa-cel

Caribou Biosciences (CRBU) will host a webcast on November 3, 2025, to report clinical data from the ANTLER Phase 1 trial of vispa-cel (CB-010) in relapsed/refractory B-NHL and first-time clinical data from the CaMMouflage Phase 1 trial of CB-011 in relapsed/refractory multiple myeloma. The Company will also outline the Phase 3 trial design for vispa-cel and development plans for CB-011. The webcast will be available live and archived on Caribou’s website.